LY354740 is a Potent and Highly Selective Group II Metabotropic Glutamate Receptor Agonist in Cells Expressing Human Glutamate Receptors-Reference-Cited by-同舟云学术

LY354740 is a Potent and Highly Selective Group II Metabotropic Glutamate Receptor Agonist in Cells Expressing Human Glutamate Receptors

Published:1997-01 Issue:1 Volume:36 Page:1-11
ISSN:0028-3908
Container-title:Neuropharmacology
language:en
Short-container-title:Neuropharmacology

Author:

SCHOEPP D.D,JOHNSON B.G,WRIGHT R.A,SALHOFF C.R,MAYNE N.G,WU S,COCKERHAM S.L,PAUL BURNETT J,BELEGAJE R,BLEAKMAN D,MONN J.A

Publisher

Elsevier BV

Subject

Cellular and Molecular Neuroscience,Pharmacology

Reference34 articles.

1. Metabotropic glutamate receptors are differentially regulated during development;Catania;Neuroscience,1994

2. Analysis of combined drug effects: a new look at a very old problem;Chou;Trends Pharmacol. Sci.,1983

3. Selective activation of phosphoinositide hydrolysis by a rigid analogue of glutamate;Desai;Neurosci. Lett.,1990

4. Cloning and expression of a human metabotropic glutamate receptor 1a: enhanced coupling on co-transfection with a glutamate transporter;Desai;Molec. Pharmacol.,1995

5. [3H]-l-2-amino-4-phosphonobutyrate labels a metabotropic glutamate receptor, mGluR4a;Ericksen;Br. J. Pharmacol.,1995

Cited by 214 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effect of mGluR2 and mGluR2/3 activators on parkinsonism in the MPTP-lesioned non-human primate;Naunyn-Schmiedeberg's Archives of Pharmacology;2024-06-20

2. Discovery and Characterization of Pyridoxal 5′-Phosphate-Dependent Cycloleucine Synthases;Journal of the American Chemical Society;2024-05-14

3. Identification of the Candidate mGlu2 Allosteric Modulator THRX-195518 through In Silico Method and Evaluation of Its Neuroprotective Potential against Glutamate-Induced Neurotoxicity in SH-SY5Y Cell Line;Current Issues in Molecular Biology;2024-01-17

4. Transferrin Receptor Protein 1 Cooperates with mGluR2 To Mediate the Internalization of Rabies Virus and SARS-CoV-2;Journal of Virology;2023-02-28

5. Targeting mGluR2/3 for treatment of neurodegenerative and neuropsychiatric diseases;Pharmacology & Therapeutics;2022-11